Skip to content
AwardedSVKGoods€792,747

Palivizumab

Published
Published 14 November 2025
Deadline
Closed 15 December 2025

Overview

Predmetom zákazky je humánny liek s názvom Palivizumab na plánované obdobie obstarávania 36 mesiacov. Medicínsko-technická špecifikácia predmetu zákazky Palivizumab 50mg/0,5ml: • Typ položky: Humánny liek • Liečivo + koncentrácia: Jedna 0,5ml injekčná liekovka obsahuje 50 mg palivizumabu. Palivizumab je rekombinantná humanizovaná monoklonálna protilátka vyrobená technológiou DNA v hostiteľských bunkách myelómu myší. • ATC skupina: J06BD01 • Lieková forma: injekčný roztok • Požadovaný počet: 2700 balení = injekčných liekoviek

Key details

Country
SVK
Status
Awarded
Category
Goods
Estimated value
€792,747
Procedure
Open
SME suitable
Yes
Published
14 November 2025
Deadline
Closed
Classification (CPV)
Immune sera and immunoglobulins

Award outcome

Awarded value
€792,746
Award date
6 March 2026
Contract period
— → 18 February 2029
Winner
  • UNIPHARMA - 1. slovenská lekárnická akciová spoločnosť

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    16 March 2026

  2. Contract Notice

    14 November 2025

Contracting authority

  • Národný ústav srdcových a cievnych chorôb, a.s.

    Procuring entity

    Bratislava, SVK

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Palivizumab — won by UNIPHARMA - 1. slovenská lekárnická akciová spoločnosť — Skim